Informations générales (source: ClinicalTrials.gov)
Interventional
Phase 2/Phase 3
University Hospital, Angers (Voir sur ClinicalTrials)
29 juin 2024
Experimentally high dose of hyperoncotic human serum albumin improve neurological
recovery after head injury reduce cerebral edema and normalize apparent diffusion
coefficient of water after ischemia reperfusion. The main hypothesis is that early
administration of hyperoncotic serum albumin is able to reduce intracranial pressure for
several days after severe head injury and thus reduce mortality and morbidity.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| AP-HP - Hôpital Bicêtre | Vigue Bernard | Contact (sur clinicalTrials) | |||
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Neurosurgical intensive care. CHU de Nancy - 54035 - Nancy - France | Audibert Gérard, MD, PhD | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Surgical intensive care. CHU - 49993 - Angers - Cedex 9 - France | ter Minassian Aram, MD, PhD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- severe head injury (GCS < 9) Next of kin informed consent
- severe head injury (GCS < 9) Next of kin informed consent
- Cranio cerebral wound Pregnancy Hypoxemia (PaO2/FiO2< 300 mmHg) Blood loss > 1/2
blood mass Renal or cardiac failure,uncontrolled hypertension Head injury dating
from more than 24 hours at the time of inclusion